Prion disease in Indigenous Australians.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
07 2021
Historique:
revised: 20 03 2020
received: 02 12 2019
accepted: 21 03 2020
pubmed: 3 4 2020
medline: 10 8 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

Indigenous Australians are at increased risk of developing dementia - Alzheimer disease and mixed dementia diagnoses are the most common. While prion diseases have been reported in Indigenous peoples of Papua New Guinea and the United States, the occurrence and phenotype of prion disease in Indigenous Australians is hitherto unreported. To report the incidence rate and clinical phenotype of Creutzfeldt-Jakob disease (CJD) in Indigenous Australians. Crude sporadic CJD (sCJD) incidence rates and indirect age standardisation of all CJD were assessed to calculate the standardised mortality ratio (SMR) of the Indigenous Australian population in comparison to the all-resident Australian population, along with analysis of clinical phenotypes. We report an illustrative case of an Indigenous Australian from regionally remote Western Australia dying from typical 'probable' sCJD 2 months after disease onset, with Australian National CJD Registry (ANCJDR) surveillance overall demonstrating eight Indigenous Australians dying from sCJD (five post-mortem confirmed, three classified as 'probable') with a clinical phenotype similar to non-indigenous people, including median age at death of 61 years (interquartile range IQR = 16 years) and median duration of illness of 3 months (IQR = 1.6 months). Indigenous Australians with sCJD were geographically dispersed throughout Australia. The calculated overall crude annual rate of sCJD in Indigenous Australians compared to the remainder of the Australian population was not significantly different (0-3.87/million for Indigenous Australians; 0.94-1.83/million for non-indigenous). The overall indirect age-standardised CJD mortality ratio for the indigenous population for the years 2006-2018 was 1.49 (95% CI, 0.75-2.98), also not significantly different to the all-resident Australian population. CJD occurs in Indigenous Australians with clinical phenotype and occurrence rates similar to non-Indigenous Australians. These findings contrast with a previous report where the incidence rate of CJD in a non-Australian indigenous population was reported to be decreased.

Sections du résumé

BACKGROUND
Indigenous Australians are at increased risk of developing dementia - Alzheimer disease and mixed dementia diagnoses are the most common. While prion diseases have been reported in Indigenous peoples of Papua New Guinea and the United States, the occurrence and phenotype of prion disease in Indigenous Australians is hitherto unreported.
AIM
To report the incidence rate and clinical phenotype of Creutzfeldt-Jakob disease (CJD) in Indigenous Australians.
METHOD
Crude sporadic CJD (sCJD) incidence rates and indirect age standardisation of all CJD were assessed to calculate the standardised mortality ratio (SMR) of the Indigenous Australian population in comparison to the all-resident Australian population, along with analysis of clinical phenotypes.
RESULTS
We report an illustrative case of an Indigenous Australian from regionally remote Western Australia dying from typical 'probable' sCJD 2 months after disease onset, with Australian National CJD Registry (ANCJDR) surveillance overall demonstrating eight Indigenous Australians dying from sCJD (five post-mortem confirmed, three classified as 'probable') with a clinical phenotype similar to non-indigenous people, including median age at death of 61 years (interquartile range IQR = 16 years) and median duration of illness of 3 months (IQR = 1.6 months). Indigenous Australians with sCJD were geographically dispersed throughout Australia. The calculated overall crude annual rate of sCJD in Indigenous Australians compared to the remainder of the Australian population was not significantly different (0-3.87/million for Indigenous Australians; 0.94-1.83/million for non-indigenous). The overall indirect age-standardised CJD mortality ratio for the indigenous population for the years 2006-2018 was 1.49 (95% CI, 0.75-2.98), also not significantly different to the all-resident Australian population.
CONCLUSION
CJD occurs in Indigenous Australians with clinical phenotype and occurrence rates similar to non-Indigenous Australians. These findings contrast with a previous report where the incidence rate of CJD in a non-Australian indigenous population was reported to be decreased.

Identifiants

pubmed: 32237029
doi: 10.1111/imj.14835
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1101-1105

Informations de copyright

© 2020 Royal Australasian College of Physicians.

Références

Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005; 64: 1586-91.
Klug GM, Wand H, Boyd A, Law M, Whyte S, Kaldor J et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain 2009; 132: 493-501.
Klug GM, Sarros S, Stehmann C, Simpson M, McLean C, Masters CL et al. Creutzfeldt-Jakob disease surveillance in Australia: update to December 2016. Commun Dis Intell (2018) 2018; 42, S2209-6051(18)00023-4).
Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51-61.
Maddox RA, Holman RC, Belay ED, Cheek JE, Yorita KL, Schonberger LB. Creutzfeldt-Jakob disease among American Indians and Alaskan natives in the United States. Neurology 2006; 66: 439-41.
Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5: 177-88.
Scrimgeour EM, Chand PR, Kenny K, Brown P. Creutzfeldt-Jakob disease in Oman: report of two cases. J Neurol Sci 1996; 142: 148-50.
Scrimgeour EM. Some recollections about kuru in a patient at Rabaul in 1978, and subsequent experiences with prion diseases. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3663-5.
Panegyres PK, McGrath F. Huntington's disease in indigenous Australians. Int Med J 2008; 38: 130-2.
Burt T, Currie B, Kilburn C, Lethlean AK, Dempsey K, Blair I et al. Machado-Joseph disease in East Arnhem Land, Australia: chromosome 14q32.1 expanded repeat confirmed in four families. Neurology 1996; 46: 11181-22.
Chen HY, Panegyres PK. The role of ethnicity in Alzheimer's disease: findings from the C-PATH online data repository. J Alzheimers Dis 2016; 51: 515-23.
Collins S, Boyd A, Lee JS, Lewis V, Fletcher A, McLean CA et al. Creutzfeldt-Jakob disease in Australia 1970-1999. Neurology 2002; 59: 1365-71.
Stehmann C, Senesi M, Lewis V, Ummi M, Simpson M, Klug G et al. Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2018. Comm Dis Intell (2018) 2019; 43.
Australian Bureau of Statistics. 3238.0 - Estimates and projections, Aboriginal and Torres Strait Islander Australians, 2006 to 2031. Table 9. 2019 [cited 2019 Aug 18]. Available from URL: https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3238.0Main+Features12001%20to%202026
Australian Bureau of Statistics. 3101.0 Australian Demographic Statistics. Table 59. 2018 [cited 2019 Jan 17]. Available from URL: https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202018
Department of Health, Australian Government. Creutzfeldt-Jakob disease surveillance in Australia: update to December 2015. 2016 [cited 2019 Aug 18]. Available from URL: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi4003k.htm
Australian Institute of Health and Welfare, Australian Government. Australian burden of disease study: impact and causes of illness and death in Indigenous and Torres Strait Islander people 2011. 2016 [cited 2019 Aug 18]. Available from URL: https://www.aihw.gov.au/reports/burden-of-disease/australian-bod-study-2011-indigenous-australians/contents/summary
Holman RC, Belay ED, Christensen KY, Maddox RA, Minino AM, Folkema AM et al. Human prion diseases in the United States. PLoS ONE 2010; 5: e8521.
Gao C, Shi Q, Tian C, Chen C, Han J, Zhou W et al. The epidemiological, clinical, and laboratory features of sporadic Creutzfeldt-Jakob disease patients in China: surveillance data from 2006-2010. PLoS One 2011; 6: e24231.
Zhao W, Zhang J-T, Xing X-W, Huang DH, Tian CL, Jia WQ et al. Chines specific characteristics of sporadic Creutzfeldt-Jakob disease: a retrospective analysis of 57 cases. PLoS One 2013; 8: e58442.
Panegyres PK. Stochastic considerations into the origins of sporadic adult onset neurodegenerative disorders. J Alzheimers Dis Parkinsonism 2019; 9: 1000473.

Auteurs

Peter K Panegyres (PK)

Neurodegenerative Disorders Research Pty Ltd, Perth, Western Australia, Australia.
The University of Western Australia, Perth, Western Australia, Australia.

Christiane Stehmann (C)

The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.

Genevieve M Klug (GM)

Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia.

Colin L Masters (CL)

The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.

Steven Collins (S)

The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.
Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH